Assay ID | Title | Year | Journal | Article |
AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1265032 | Cytotoxicity against human HCT116 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265036 | Cytotoxicity against human HL60 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID240619 | Inhibitory concentration against cytochrome P450 2D6 | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
| Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. |
AID1265044 | Inhibition of human topoisomerase-2alpha-mediated relaxation of supercoiled plasmid pBR322 DNA after 30 mins by ethidium bromide staining | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265031 | Cytotoxicity against human A549 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265037 | Cytotoxicity against mouse P388 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265038 | Cytotoxicity against mouse L1210 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265045 | Induction of DNA damage in human A549 cells assessed as phosphorylation of H2AX histone at IC90 after 3 hrs by fluorescence microscopy | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265033 | Cytotoxicity against human HT-29 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265039 | Cytotoxicity against mouse WEHI1640 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265035 | Cytotoxicity against human MCF7 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265043 | Inhibition of human topoisomerase-1-mediated relaxation of supercoiled plasmid pBR322 DNA at 1 to 100 uM after 30 mins by ethidium bromide staining | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265040 | Cytotoxicity against mouse NIH/3T3 cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID211128 | Relative potency to cause 90% of topoisomerase II-mediated cleavage of liner 8.4-kb YEPG DNA | 1994 | Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
| Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin. |
AID188438 | Nuclear count minus the highest cytoplasmic count determined in rat hepatocytes for each cell | 1994 | Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
| Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin. |
AID1265034 | Cytotoxicity against human LNCAP cells after 120 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265046 | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at IC90 after 24 hrs using propidium iodide staining by flow cytometry analysis | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265050 | Cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at IC90 after 24 to 120 hrs using propidium iodide staining by flow cytometry analysis | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265051 | Cell cycle arrest in human HL60 cells assessed as abnormal mitotic figures at IC90 after 24 to 120 hrs using propidium iodide staining by flow cytometry analysis | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265053 | Induction of apoptosis in human HL60 cells assessed as micronucleated cells at IC90 up to 120 hrs using Hoechst-33342 staining by fluorescent microscope analysis relative to BAT | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265052 | Induction of apoptosis in human HL60 cells assessed as increase of debris fraction at IC90 up to 120 hrs using Hoechst-33342 staining by fluorescent microscope analysis relative to BAT | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265049 | Induction of apoptosis in human A549 cells assessed as change in nuclear and cellular morphology at IC90 up to 120 hrs using Hoechst-33342 staining by fluorescent microscope analysis | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID15769 | Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts | 1994 | Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
| Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin. |
AID43725 | Tested for the inhibitory activity against CCRF CEM T- cell leukemia cells | 1994 | Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
| Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin. |
AID1265047 | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at IC90 after 120 hrs using propidium iodide staining by flow cytometry analysis | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
AID1265054 | Induction of apoptosis in human HL60 cells assessed as fraction of polyploid cells at IC90 up to 120 hrs using Hoechst-33342 staining by fluorescent microscope analysis relative to BAT | 2015 | European journal of medicinal chemistry, Dec-01, Volume: 106 | Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |